Importantly, we reported the first evidence of clinical benefit achieved with the TRKA-targeted agent entrectinib in a CRC patient bearing a LMNA-NTRK1 positive tumor, providing clinical validation of activated TRKA as a target in CRC [7]. Here, NTRK1 is linked to colorectal carcinoma.